Research progress in the anti-inflammatory effect of PCSK9 inhibitors in atherosclerotic cardiovascular disease

Hyperlipidemia is an important risk factor for atherosclerotic cardiovascular disease (ASCVD), and lipid-lowering therapy is an important part of ASCVD treatment. In recent years, PCSK9 inhibitors, proven to have potent LDL-C lowering effects, have been recommended by several guidelines as an important method for lipid-lowering therapy. With the deepening of research, PCSK9 inhibitors not only have the effect of lowering LDL-C, but also play a certain degree of anti-inflammatory effect. This article reviews the anti-inflammatory effect of PCSK9 inhibitors in ASCVD from the perspective of the involvement of PCSK9 in inflammatory responses.